Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma

Jun Zeng (tonypersist@126.com)
Chengdu medical college

Xianggui Yang
Chengdu Medical College

Li Yang
Chengdu Medical College

Wancheng Li
Chengdu Medical College

Yaxin Zheng
Chengdu Medical College

Research

Keywords: Thymosin β10, macrophages, Proliferation, phenotype conversion, PI3K/Akt, Lung adenocarcinoma

DOI: https://doi.org/10.21203/rs.3.rs-34263/v2

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Thymosin β10 (TMSB10) has been reported to play a protumorigenic role in a majority of solid cancers. However, the existence of TMSB10 in immune microenvironment may contribute to the pathogenesis of lung adenocarcinoma has not been previously explored.

Method: TAMs-associated TMSB10 expression was evaluated by immunohistochemistry (IHC) in 184 lung adenocarcinomas. Xenograft mice model was established to investigate the effect of TMSB10 shRNA on TAMs phenotypes. The macrophages phenotype associated cytokines IL-6, IL-8, IL-12 and TNF-α were detected by ELISA after treated with TMSB10 shRNA or scramble. Furthermore, the target proteins were detected by immunoblot.

Results: We found that high TAMs-associated TMSB10 expression was significantly correlated with the advanced TNM stage and T3/T4 tumor size. And high TAMs-associated TMSB10 expression was significantly correlated with poor overall and progression-free survival of lung adenocarcinoma, acting as an independent prognostic factor for lung adenocarcinoma. Furthermore, we investigated the biological functions of TMSB10 in macrophages in vivo and in vitro. TMSB10 knockdown dramatically reduced TAMs, THP-1 and RAW264.7 cell proliferation, and promoted macrophages phenotype conversion of M2 to M1, and TMSB10 knockdown reduced the levels of p-Akt (Sec473), p-mTOR (Sec2448) and p-p70S6K (Thr389) without effect on Akt, mTOR and p70S6K expression.

Conclusions: These results demonstrate that TAMs-associated TMSB10 promotes tumor growth through increasing TAMs M2 conversion and proliferation via PI3K/Akt signaling pathway, providing a promising tumor biomarker for predicting prognosis and a potential therapeutic target for lung adenocarcinoma.

Background

Although lung cancer morbidity shows a continuous tendency to decline in recent years, yet lung cancer accounts for a quarter of all cancer deaths worldwide (1). Even these patients with stage I and II non-small cell lung cancer (NSCLC) received radical resection, nonsurgical approaches such as stereotactic body radiotherapy (SBRT) or Radiofrequency ablation, postoperative recurrence rate reach to over 30% in patients with early stage NSCLC (2, 3). For stage III NSCLC, the multimodality therapies including surgical removal, chemotherapy, radiotherapy or targeted therapy, is preferable in the subsets of patients (4). The number of postoperative patients that could benefit from the adjuvant therapies is limited (5, 6). For lung adenocarcinoma is the most prevalent subtype of lung cancer, it is urgent to develop new treatment strategies for those recurrent patients. In recent years, the great value of immunotherapy in anticancer treatment has been confirmed, which accelerate the exploration of diverse effective immunotherapeutic strategies for various malignancies. The immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) were the most promising targets, meanwhile their immunosuppressants have been clinically demonstrated effective in
NSCLC, melanoma and bladder cancer et al (7-12). However, acquired resistance to immunotherapies was unavoidable after receiving immune checkpoints blockade (13, 14).

Tumor-associated macrophages (TAMs) are the major component of the tumor immune microenvironment in solid tumors, which help tumor cells to escape immune surveillance by recruiting immunosuppressors like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (15). Since TAMs are mainly consisted by antitumorigenic M1 phenotype macrophages and protumorigenic M2 phenotype macrophages, studies try to restore the antitumorigenic talents of macrophages and repress protumorigenic TAMs are prevailing in recent years (15). Manipulating these arsenals of the innate immunity combined with known curative immunotherapies that activate the adaptive immunity looks more promising than either therapy alone.

Thymosin β10 (TMSB10) belongs to the family of β-thymosins which contain highly conserved amino acid sequence (16). TMSB10 mainly serve as actin sequestering proteins to inhibit the formation of F-actin. TMSB10 also has been proven to be overexpressed in most human solid tumors, and regulate cancer cell proliferation and metastasis (17-21). Notably, Yonit Lavin et al. reported that TMSB10 mRNA was unregulated in TAMs of early lung adenocarcinoma compared with those in mononuclear macrophages of adjacent normal lung tissues and peripheral blood (22).

However, the relation between TMSB10 and TAMs remains unclear, which needed to be furtherly clarified. To the best of our knowledge, this is the first study to explore the role of TMSB10 in early lung adenocarcinoma through analyzing the relation between its clinicopathological characteristics and TAMs-associated TMSB10. Moreover, we conducted the experiments in vitro and in vivo to investigate the biological effect of TMSB10 on TAMs phenotype.

Methods

Clinical data. The clinicopathological and survival data were obtained from patients with lung adenocarcinoma who had undergone surgery between January 2013 and December 2019. Tumors were classified according to the 8th edition of the AJCC TNM system for lung cancer. The inclusion criteria were as follows: (1) primary lung adenocarcinoma diagnosed by pathological diagnosis; (2) cases had received no previous treatment before operation. The age, gender, smoking history, tumor site, tumor size, lymphatic metastasis, TNM stage, and survival information were acquired from medical records. This retrospective study was approved by the ethics committee of our hospital, and the informed consent was exempted.

Animal models. The mouse adenocarcinoma cell line (LLC) was purchased from ATCC (Manassas, USA). LLC were cultured in DMEM supplemented with 10% FBS. All C57BL/6 mice were obtained from the vital river company (Beijing, China). For tumor growth experiments, $2 \times 10^6$ LLC cells were suspended in 100ul of DMEM and injected subcutaneously into the right back of 6 weeks old male mice. Mice were randomly divided into experimental group or control (scramble) group matched for the tumor volumes on day 4
post tumor inoculation. The experimental group mice were injected intravenously with TMSB10 shRNA lentivirus (4 × 10^9 PFU, GENE, Shanghai) every week, and scramble cohorts were injected intravenously with equivalent scramble shRNA lentivirus. Tumor sizes were measured with calipers each 5 days throughout the in vivo experiment.

**Isolation of tumor-infiltrating immune cells.** The excised tumors were finely minced and suspended in HBSS (Thermo Fisher, 14025134) supplemented with 2%FBS (Gibco, 1921005PJ), 1% hyaluronidase (Sigma, 37326-33-3), Collagenase 4 at 1mg/mL (Sigma, SCR103) and 0.25% DNase I (Roche, 11284932001) at 37°C on a shaker at 80rpm for 2 hours. The mixture was then mixed with 10% PBS (suspended in HBSS) in a 1:1 ratio and filtered through a 50um mesh. Percoll (Sigma, P1644) was used to purify tumor-infiltrating leukocytes (TILs) via density gradient centrifugation. Briefly, 60% Percoll was firstly added to the bottom of a glass tube and then 30% Percoll was carefully added by a Pasteur pipette. Finally, the filtered cells were gently resuspended in the 30% Percoll. The suspension was centrifuged at 400g for 25 min at room temperature. After centrifugation, the pellet of erythrocytes and excess buffer/percoll were removed, leaving a purified population of leukocytes at the interface. The purified tumor-infiltrating leukocytes were washed twice with FACS buffer prior to flow cytometry analysis.

**Flow cytometry.** Cell staining was operated on ice and away from light. For surface staining, the purified cells from tumor tissues were incubated with mouse Fc block (1:200, BD Biosciences, BD553141) in 4°C for 30 min before staining with relevant conjugated antibodies. The relevant fluorescent-labeled antibodies were diluted in FACS buffer and applied to incubate for 30 min. For intracellular staining, cells were subsequently washed by FACS buffer and fixed (Fixation and Permeabilization Solution, BD Biosciences, BD554722), then the relevant fluorescent-labeled antibodies, diluted in Perm/Wash Buffer (BD Biosciences, BD557885), were used to incubate for 30 min. Upon staining, cells were resuspended in FACS buffer (25mM HEPES, 2% FBS, 10mM EDTA, 0.1% sodium azide in PBS) and passed through 50um mesh filter before flow cytometry analysis. The stained cells were run on a BD LSRFortessa X-20 Flow Cytometer equipped with FACSDiva software (BD Biosciences). FlowJo software (Treestar) was applied for analyzing flow cytometry data. Forward scatter (FSC) and side scatter (SSC) were used to gate on single nucleated cells and to eliminate cell debris and doublets.

**Immunoblotting and ELISA assay.** THP-1 and RAW264.7 cell lines were cultured in RPMI-1640 medium supplemented with 10% FBS. After treatment with indicated shRNA lentivirus (MOI 10), lipopolysaccharide (LPS) (100 ng/ml) or IL-4 (15 ng/ml) for 72 hr, THP-1 and RAW264.7 cells were harvested in RIPA buffer (Sigma-Aldrich) supplemented with protease inhibitors and phophatase inhibitors (Roche). Next, equal amounts of total protein lysates (40 μg) were separated by SDS-PAGE before transferred to a PVDF microporous membrane, and stained with antibodies against TMSB10 (1:1000, Sant cruz, sc-514309), AKT (1:1000, Abcam, ab8805), p-AKT(Ser473) (a1:3000, Abcam, ab81283), mTOR (1:2000, Abcam, ab2732), p-mTOR(sec2448) (1:1000, Abcam, ab109268), p70S6K (1:2000, CST, 9202S), p-p70S6K(Thr389) (1:1000, CST, 9234T) and GAPDH (1:5000,CST, 5174S) as previously described (19). Meanwhile, the extracellular IL-6, IL-10, IL-12 and TNF-α levels in serum-free
conditioned media from THP-1 and RAW264.7 cells treated with indicated lentivirus, LPS or IL-4 for 72 hr were measured using the ELISA kit (Elabscience, Wuhan).

**Immunohistochemistry.** Immunohistochemical assay was performed on the 5 mm thick slides, using mouse anti-human TMSB10 (1:500, Sant cruz, sc-514309) and CD68 (1:1000, CST, 76437) primary antibody, as previously (23). Two experienced investigators independently scored the TAMs-associated TMSB10 without knowing the clinical data. The proportion of positive macrophage was scored as 0 (0–9% positive macrophages), 1 (10–25% positive macrophages), 2 (26–50% positive macrophages) and 3 (>50% positive macrophages) respectively. Staining intensity was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining). The final scores ranged from 0 to 3, ≥2 score was defined as high TAMs-associated TMSB10 expression and <2 score was defined as low TAMs-associated TMSB10 expression according to previous method (18).

Cell proliferation assay

The THP-1 and RAW264.7 cells proliferation were measured by a Cell counting Kit-8 (CCK-8) kit (Beyotime, Shanghai, China). Briefly, cells were seeded into 96-well plates. After transfection of indicated shRNA lentivirus for 72 hr, the WST-8 reagent was added to each well for 1 hr incubation. The optical density (OD) value (450 nm) was measured using a microplate reader.

**Statistical analysis.** Statistical analyses were performed by SPSS 22.0 software (IBM Corporation, NY, USA). The correlation between TMSB10 expression and clinical pathological variables were investigated by Chi-square test. The Kaplan-Meier method and Cox proportional hazard model were used to investigate the prognostic factors for progression free survival (PFS) and overall survival (OS). Unpaired two-tailed Student's t tests and/or analysis of variance (ANOVA) were used to calculate the significance. *P* < 0.05 was considered significant unless otherwise noted.

**Results**

High TAMs-associated TMSB10 is correlated with clinicopathologic characteristics of lung adenocarcinoma.

A total 257 cases with lung adenocarcinoma were preliminary enrolled in our study. 73 cases of them were initially excluded: (1) 65 patients had received systemic therapy before enrollment and (2) 8 cases had other malignancies or multiple primary tumors. Finally, 184 cases were enrolled in this study. The clinicopathologic features of the enrolled 184 cases were presented in Table I. The average age of diagnosis was 63 years (age from 35 to 86 years) with mean follow-up of 37 months (range from 4 to 83 months). Of the whole patients, 44.6% were female, 49.5% were non-smokers, 64.1% were at stage 1 + II and 35.9% were at stage III, 114 patients (62.0%) showed no lymphatic metastasis.

As TAMs is crucial for lung cancer progression, those genes that promote protumorigenic M2 polarization of TAMs might promote cancer progression. We found the CD 68 protein was mainly expressed in TAMs.
and TMSB10 protein was expressed in both tumor cells and TAMs (Fig. 1A-1D). High TAMs-associated TMSB10 expression preferred to be detected in older patients ($P < 0.001$). High TAMs-associated TMSB10 expression was significantly associated with advanced TNM stage ($P = 0.036$) and T3/T4 tumor size ($P = 0.007$) (Table I), indicating TAMs-associated TMSB10 might contribute to tumor proliferation or metastasis. There are no statistically differences in the relation between TAMs-associated TMSB10 expression and other clinicopathologic characteristics.

**High TAMs-associated TMSB10 is correlated with the poor prognosis of lung adenocarcinoma.**

To investigate the prognostic value of TAMs-associated TMSB10 in patients with lung adenocarcinoma, we had collected follow-up data and performed survival analysis. Kaplan-Meier analysis showed that patients with low TAMs-associated TMSB10 expression had significantly better PFS (5-year survival rate: 53.0% versus 30.1%, $P = 0.002$) as well as better OS (5-year survival rate: 57.0% versus 25.0%, $P < 0.001$) compared with those with high TAMs-associated TMSB10 expression (Fig. 1E, 1F).

The Cox regression analysis of PFS showed that high TAMs-associated TMSB10 expression (HR: 1.726, 95%CI: 1.061–2.808, $P = 0.028$) might be independent risk factors of PFS. Meanwhile, it was also showed that high TAMs-associated TMSB10 expression (HR: 1.94, 95%CI: 1.189–3.167, $P = 0.008$) might be independent risk factors of OS.

**TAMs-associated TMSB10 knockdown represses tumor growth**

To identify the effect of TAMs-associated TMSB10 on the progression of lung adenocarcinoma, we conducted a xenograft model. The LLC subcutaneously injected mice received TMSB10 shRNA and scramble shRNA lentivirus intravenously, respectively (Fig. 2A). We found that TMSB10 knockdown significantly attenuated the growth of lung adenocarcinomas (Fig. 2B). And the infiltrating TAMs and TAMs-associated TMSB10 expression reduced by TMSB10 knockdown (Fig. 2C). Therefore, we speculated that TMSB10 knockdown might repress the M2 phenotype and proliferation of macrophages.

**TMSB10 knockdown promotes macrophages M1 conversion and inhibits macrophages proliferation.**

We further performed flow cytometry analysis of total TAMs (CD45+CD11b+F4/80+CSF1R+), M1 phenotype TAMs (CD11b+F4/80+CSF1R+CD68+CD206+), M2 phenotype TAMs (CD11b+F4/80+CSF1R+CD68+CD206+) and Tregs (CD45+Foxp3+CD4+) subpopulations of LLC tumors derived from xenograft mice. And we found that the proportion of CSF1R+ TAMs in CD45+ TILs was reduced in TMSB10 knockdown xenograft tumors (Fig. 3A). Meanwhile, the proportion of M2 TAMs in total CSF1R+ TAMs and the proportion of Foxp3+ Tregs in CD45+ TILs were dramatically reduced in TMSB10 knockdown group compare to those in scramble group (Fig. 3B, 3C).

We next explored the biological role of TMSB10 in macrophages in vitro. Given LPS could facilitate macrophages M1 polarization, and IL-4 could induce macrophages M2 polarization. We found the macrophage M1 markers IL-6 and IL-12 in TMSB10 knockdown group or in LPS group were secreted...
more than in IL-4 group, and TNF-α in TMSB10 knockdown group secreted more than in LPS group or in IL-4 group. However, the macrophage M2 marker IL-10 was secreted significantly less in TMSB10 knockdown group or in LPS group than in IL-4 group (Fig. 4A, 4B). Meanwhile, the proliferation of THP-1 and RAW264.7 cells was significantly inhibited by TMSB10 knockdown ($P < 0.05$) (Fig. 4C).

**TMSB10 promotes macrophages M2 conversion and proliferation via PI3K/Akt pathway.**

A previous study reported that PI3K/Akt signal was the downstream pathway of TMSB10 and played a key role in promoting breast cancer growth and metastasis by activating the Akt/FOXO pathway (19). To investigated the underlying mechanisms of the biological effect of TMSB10 on macrophages, we intended to explore the PI3K/Akt signaling pathway. We detected PI3K/Akt pathway proteins in THP-1 and RAW264.7 cells stably-transfected with TMSB10 shRNA and scramble shRNA. We found that TMSB10 knockdown could reduce the levels of p-Akt (Ser473), p-mTOR (Ser2448) and p-p70S6K (Thr389), but had no effect on Akt, mTOR and p70S6K expression levels (Fig. 4D).

Furthermore, we found that TMSB10 overexpression could activate the PI3K/Akt signaling pathway by increasing the levels of p-Akt (Ser473), p-mTOR (Ser2448) and p-p70S6K (Thr389) without changing the levels of Akt, mTOR and p70S6K in THP-1 and RAW264.7 cells (Fig. 4D). Overall, these results suggested that the PI3K/Akt signaling pathway was involved in TMSB10-induced M2 phenotype conversion and proliferation of macrophages.

**Discussion**

TMSB10, a 43-amino acid residues β-thymosin, is found to be overexpressed in human lung cancer, liver cancer, breast cancer, ovarian cancer, gastric cancer, pancreatic cancer, thyroid cancer and renal cell carcinoma et al (18, 21, 24-28). And TMSB10 mRNA is found to be overexpressed in TAMs of early lung adenocarcinoma compared with in adjacent normal lung macrophages and peripheral blood monocytes (22). However, the clinicopathological significance of TAMs-associated TMSB10 in lung cancer remains largely unknown. We firstly carried out the investigation on the relationship between TAMs-associated TMSB10 and the clinicopathological features of lung adenocarcinoma. First, we found that high TAMs-associated TMSB10 expression was significantly associated with advanced TNM stage and bigger tumor size. Moreover, High TAMs-associated TMSB10 was significantly correlated with poor PFS and OS. Next, we conducted xenograft model to investigate the role of TMSB10 in tumors. We found that TMSB10 knockdown significantly attenuated the xenograft tumor growth, and the infiltrating TAMs and TAMs-associated TMSB10 expression was reduced by TMSB10 knockdown. Nevertheless, The biological role of TMSB10 in lung adenocarcinoma TAMs was still unknown.

Most studies showed that knockdown of TMSB10 reduced cancer cell proliferation or migration (18, 19, 29-31). However, Lee et al. reported that overexpression of TMSB10 caused F-actin stress fibers disruption, notably reduced cell growth and increased apoptosis (24). Zhang et al. showed that TMSB10 played a contradictory role in cell proliferation in different kind of cell (32). Therefore, in order to investigating the role of TMSB10 in TAMs of lung adenocarcinoma, we isolated the tumor-
infiltrating immune cells in xenograft tumors, and found that CSF1R$^+$ TAMs and Foxp3$^+$ Tregs were reduced in TMSB10 knockdown group. TMSB10 knockdown could significantly promote the M2 to M1 phenotype conversion of TAMs in vivo. Meanwhile, the proliferation of macrophages was repressed by TMSB10 knockdown. And the level of macrophage M1 markers IL-6, IL-12 and TNF-α were increased by TMSB10 knockdown, yet the level of macrophage M2 marker IL-10 was repressed by TMSB10 knockdown in vitro. Further studies are needed to elucidate the underling mechanism for its biological role.

PI3K/Akt is an important pathway for cellular growth, survival and protein synthesis. Recent studies have reported that resident macrophages can proliferate via different signaling so as to maintain cell number in type 2 immunity (33, 34). Meanwhile, the anti-inflammatory M2 macrophage could been activated by PI3K/Akt signaling (35). We further demonstrated that THP-1 and RAW264.7 cells could proliferate rapidly and be converted to M2 phenotype by activating TMSB10-dependent PI3K/Akt signaling pathway.

**Conclusions**

In summary, these results demonstrated that TMSB10 was remarkably overexpressed in TAMs and negatively associated with the prognosis of lung adenocarcinoma, and TMSB10 knockdown dramatically repressed xenograft tumor growth in vivo. TMSB10 knockdown promoted antitumorgenic M1 conversion and repressed the proliferation of macrophages via PI3K/Akt signaling in vivo and in vitro. Taken together, our findings suggest that TAMs-associated TMSB10 promotes tumor through increasing TAMs proliferation and M2 phenotype conversion via PI3K/Akt signaling, which might be an indicator for prognosis, seems as a promising novel therapeutic target for human lung adenocarcinoma.

**Abbreviations**

TAMs: Tumor-associated macrophages; Tregs: Regulatory T cells; NSCLC: Non-small cell lung cancer; LLC: Lewis lung cancer. MDSC: myeloid-derived suppressor cells; FSC: Forward scatter; SSC: Side scatter.

**Declarations**

**Consent for publication**

Not applicable.

**Availability of data and materials**

The software, databases and all relevant raw data are freely available to scientists.

**Conflict of interest**

The authors declare that they have no conflict of interest.
Funding: This work was supported by the Foundation for High-level Talents of the First Affiliated Hospital of Chengdu Medical College (CYFY-GQ03), the Special Fund of National Key Clinical Specialties (CYFY2017GLPHX04) and the Natural Science Foundation of China (81600388).

Author contributions: JZ, XGY and YXZ designed and performed experiments, YXZ analyzed data, YL and WCL analyzed histology, and ZJ wrote the manuscript.

Acknowledgements

None.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018; 68(1): 7-30.
2. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS, Wu YC. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012; 7(7): 1115-23.
3. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e278S-e313S.
4. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e314S-e40S.
5. Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, et al. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA oncology. 2017; 3(5): 610-9.
6. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017; 35(25): 2960-74.
7. PM F, JE C, KN S, V A, TR C, MD H, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018; 378(21): 1976-86.
8. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015; 373(2): 123-35.
9. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine. 2015; 372(21): 2018-28.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015; 373(1): 23-34.

11. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528): 558-62.

12. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, NY). 2018; 359(6382): 1350-5.

13. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer discovery. 2016; 6(8): 827-37.

14. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Ky is a molecular switch that controls immune suppression. Nature. 2016; 539(7629): 437-42.

15. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature reviews Drug discovery. 2018; 17(12): 887-904.

16. Sribenja S, Wongkham S, Wongkham C, Yao Q, Chen C. Roles and mechanisms of β-thymosins in cell migration and cancer metastasis: an update. Cancer Invest. 2013; 31(2): 103-10.

17. S S, M L, S W, C W, Q Y, C C. Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer investigation. 2009; 27(10): 1016-22.

18. Song C, Su Z, Guo J. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma. Bioscience reports. 2019; 39(3).

19. Zhang X, Ren D, Guo L, Wang L, Wu S, Lin C, et al. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast cancer research : BCR. 2017; 19(1): 15.

20. Zhang XJ, Su YR, Liu D, Xu DB, Zeng MS, Chen WK. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. The Journal of surgical research. 2014; 192(2): 487-93.

21. Lee SM, Na YK, Hong HS, Jang EJ, Yoon GS, Park JY, et al. Hypomethylation of the thymosin β(10) gene is not associated with its overexpression in non-small cell lung cancer. Molecules and cells. 2011; 32(4): 343-8.

22. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017; 169(4): 750-65 e17.

23. Chen MC, Chen KC, Chang GC, Lin H, Wu CC, Kao WH, et al. RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer. Cell death & disease. 2020; 11(4): 265.

24. Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH, Kim JW, et al. Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene. 2001; 20(46): 6700-6.
25. Oien KA, Vass JK, Downie I, Fullarton G, Keith WN. Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene. 2003; 22(27): 4287-300.
26. Li M, Zhang Y, Zhai Q, Feurino LW, Fisher WE, Chen C, et al. Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. Cancer Invest. 2009; 27(3): 251-6.
27. Fehér LZ, Pocsay G, Krenács L, Zvara A, Bagdi E, Pocsay R, et al. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. Pathology oncology research : POR. 2012; 18(2): 449-58.
28. Xiao R, Shen S, Yu Y, Pan Q, Kuang R, Huang H. TMSB10 promotes migration and invasion of cancer cells and is a novel prognostic marker for renal cell carcinoma. International journal of clinical and experimental pathology. 2019; 12(1): 305-12.
29. Alldinger I, Dittert D, Peiper M, Fusco A, Chiappetta G, Staub E, et al. Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al]. 2005; 5(4-5): 370-9.
30. Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C. Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest. 2009; 27(10): 1016-22.
31. Santelli G, Califano D, Chiappetta G, Vento MT, Bartoli PC, Zullo F, et al. Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. The American journal of pathology. 1999; 155(3): 799-804.
32. Zhang W, Chu W, Liu Q, Coates D, Shang Y, Li C. Deer thymosin beta 10 functions as a novel factor for angiogenesis and chondrogenesis during antler growth and regeneration. Stem cell research & therapy. 2018; 9(1): 166.
33. NN J, EA S, TR B, I S, CC L, SC H, et al. Bhlhe40 mediates tissue-specific control of macrophage proliferation in homeostasis and type 2 immunity. Nature immunology. 2019; 20(6): 687-700.
34. Rückerl D, Jenkins SJ, Laqtom NN, Gallagher IJ, Sutherland TE, Duncan S, et al. Induction of IL-4Rα-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood. 2012; 120(11): 2307-16.
35. J VdB, B M, A M, P DB, JA VG. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood. 2012; 119(7): 1623-33.

Table

Table I. The Correlation between TAMs-associated TMSB10 expression and clinicopathological characteristics of lung adenocarcinoma.
| Variables                        | All, N(%) | TAMs-associated TMSB10 expression | P  |
|---------------------------------|-----------|----------------------------------|----|
|                                 | Low, N(%) | High, N(%)                       |    |
| Age, mean ± SD                  | 63.0 ± 9.9| 59.2 ± 8.1                       | 64.7 ± 10.1 | < 0.001 |
| < 65                            | 102(55.4) | 43(75.4)                         | 59(46.5) | < 0.001 |
| ≥ 65                            | 82(44.6)  | 14(24.6)                         | 68(53.5) |
| Gender                          |           |                                  |    |
| Male                            | 102(55.4) | 30(51.7)                         | 72(57.1) | 0.608 |
| Female                          | 82(44.6)  | 28(48.3)                         | 54(42.9) |
| Smoking history                 |           |                                  |    |
| Smoker                          | 93(50.5)  | 29(50.9)                         | 64(50.4) | 0.952 |
| Non-smoker                      | 91(49.5)  | 28(49.1)                         | 63(49.6) |
| Tumor site                      |           |                                  |    |
| Upper or middle                 | 126(68.5) | 40(70.2)                         | 86(67.7) | 0.740 |
| Lower                           | 58(31.5)  | 17(29.8)                         | 41(32.0) |
| Tumor size                      |           |                                  |    |
| T1 + T2                         | 158(85.9) | 43(75.4)                         | 115(90.6) | 0.007 |
| T3 + T4                         | 26(14.1)  | 14(24.6)                         | 12(9.4)  |
| Lymphatic metastasis            |           |                                  |    |
| N0                              | 114(62.0) | 35(60.3)                         | 79(62.7) | 0.666 |
| N1–N3                           | 70(38.0)  | 23(39.7)                         | 47(37.3) |
| TNM stage                       |           |                                  |    |
| I + II                          | 118(64.1) | 42(73.7)                         | 76(59.8) | 0.036 |
| III                             | 66(35.9)  | 15(26.3)                         | 51(40.2) |